Colorectal Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Colorectal Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 7 (July)

1. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
   J Natl Cancer Inst, 98(13): 920-31. [Abstract] [Full-text]
2. Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility?
   Br J Radiol, 79(943): 578-83. [Abstract] [Full-text]
3. PET/CT detects abdominal wall and port site metastases of colorectal carcinoma.
   Br J Radiol, 79(943): 572-7. [Abstract] [Full-text]
4. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.
   Oncogene, 25(29): 4116-21. [Abstract] [Full-text]
5. Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study.
   BMJ, 333(7558): 69-70. [Abstract] [Full-text]
6. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer.
   Clin Microbiol Infect, 12(8): 782-6. [Abstract] [Full-text]
7. Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines.
   Exp Cell Res, 312(13): 2433-42. [Abstract] [Full-text]
8. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients.
   Gynecol Oncol, 102(2): 189-94. [Abstract] [Full-text]
9. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
   J Clin Oncol, 24(21): 3354-60. [Abstract] [Full-text]
10. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    J Clin Oncol, 24(21): 3347-53. [Abstract] [Full-text]
11. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
    Proc Natl Acad Sci U S A, 103(29): 11003-8. [Abstract] [Full-text]
12. Does a negative screening colonoscopy ever need to be repeated?
    Gut, 55(8): 1145-50. [Abstract] [Full-text]
13. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment.
    Gut, 55(8): 1151-5. [Abstract] [Full-text]
14. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.
    Gut, 55(8): 1156-64. [Abstract] [Full-text]
15. Salvaging their normal lives: a qualitative study of patients with recently diagnosed advanced colorectal cancer.
    Oncol Nurs Forum, 33(4): 719-25. [Abstract] [Full-text]
16. Mucinous adenocarcinoma arising from fistula in ano: MRI findings.
    AJR Am J Roentgenol, 187(2): 517-21. [Abstract] [Full-text]
17. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy.
    AJR Am J Roentgenol, 187(2): W202-8. [Abstract] [Full-text]
18. High Pin1 expression is associated with tumor progression in colorectal cancer.
    J Surg Oncol, 94(2): 155-60. [Abstract] [Full-text]
19. Monoclonal antibody conjugated to gadolinium as a contrast agent for magnetic resonance imaging of human rectal carcinoma.
    J Surg Oncol, 94(2): 144-8. [Abstract] [Full-text]
20. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma.
    J Surg Oncol, 94(2): 132-7. [Abstract] [Full-text]
21. Effect of dietary caraway (Carum carvi L.) on aberrant crypt foci development, fecal steroids, and intestinal alkaline phosphatase activities in 1,2-dimethylhydrazine-induced colon carcinogenesis.
    Toxicol Appl Pharmacol, 214(3): 290-6. [Abstract] [Full-text]
22. ICAM-1 inhibits the homocluster formation of MHC-I in colon carcinoma cells.
    Biochem Biophys Res Commun, 347(3): 758-63. [Abstract] [Full-text]
23. Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer.
    J Clin Oncol, 24(22): 3570-5. [Abstract] [Full-text]
24. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
    J Clin Oncol, 24(22): 3562-9. [Abstract] [Full-text]
25. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
    J Clin Oncol, 24(22): 3542-7. [Abstract] [Full-text]
26. Physical activity and survival after colorectal cancer diagnosis.
    J Clin Oncol, 24(22): 3527-34. [Abstract] [Full-text]
27. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
    J Clin Oncol, 24(22): 3535-41. [Abstract] [Full-text]

© 2004-2010 Colorectal Cancer Research Today. All Rights Reserved.